Related Experiment Video
Updated: Sep 8, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights
Dandan Qiu1, Jingjing Wang1, Aijuan Li1
1National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Xuanwu District, No. 305 East Zhongshan Road, Nanjing, 210016, Jiangsu, China.
Purpose:
To evaluate the short-term efficacy and safety of finerenone in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD).
Methods:
A retrospective cohort study was conducted on a relatively small sample of 23 patients diagnosed with T1D and CKD between January 2023 and August 2024. All patients received renin-angiotensin system inhibitors (RASi), with 12 patients additionally treated with finerenone.
Results:
The cohort had a median age of 34 (29, 39) years, including 11 females. Median Hemoglobin A1c (HbA1c) was 7.30% (6.55, 8.10%), proteinuria was 1.49 (0.88, 2.84) g/24h, mean estimated glomerular filtration rate (eGFR) was 71.91 ± 24.59 mL/min/1.73m2, and serum potassium was 4.47 ± 0.39 mmol/L. After 6 months of follow-up, eGFR declined significantly in the control group (- 10.55 ± 14.61 mL/min/1.73m2, P = 0.038) but remained stable in the finerenone group (- 1.34 ± 11.98 mL/min/1.73m2, P = 0.706). No significant changes were observed in proteinuria, serum potassium, blood pressure, or other metabolic parameters in either group. No cases of hyperkalemia or acute kidney injury (AKI) were observed among patients who completed the 6-month follow-up.
Conclusion:
In this preliminary study, finerenone showed potential for attenuating kidney function decline in patients with T1D and CKD, though its long-term efficacy and safety require validation in larger trials.
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute Kidney Injury I: Introduction

